Preliminary Agenda

8:00

Welcome and Introductions
Chloe Yang

8:10

Keynote Presentation: Sequencing targeted myeloma therapy
Adam Cohen
8:50

Practical application of minimal residual disease (MRD) testing
Suzanne Trudel

9:30

Keynote Presentation; Treatment-related eye toxicity in myeloma
Shaun Singer
10:10

Break
10:30

Small Group Case-Based Breakout Sessions. Sessions are fully interactive between faculty and participants

Group 1; Relapsed/refractory myeloma
Drs. A.Cohen, S. Trudel

Group 2; Frontline myeloma therapy
Drs. S. Bhella, C.Yang

Group 3; Supportive care – Bone disease, eye toxicity, infections
Drs. G.Lancman, D.Reece, S.Singer

Group 4; Amyloidosis and Waldenstrom Macroglobulinemia
Drs. V.Kukreti, C.Chen
11:30

Lunch break

12:15

Updates in light chain amyloidosis
Vishal Kukreti
12:45

Fine-tuning management of the transplant-ineligible patient
Sita Bhella
1:15

Current state of Waldenstrom Macroglobulinemia
Christine Chen
1:45

Clinical trials at Princess Margaret
Guido Lancman
2:15

PM Myeloma Treatment Policies and Closing Remarks
Chloe Yang